Advertisement

Boon-Cher Goh, MD, on Cancer Drugs in Singapore: 3As (Availability, Accessibility, and Affordability)

First International Summit on Interventional Pharmacoeconomics

Advertisement

Related Videos

Peter Clark, MA, MD, FRCP: A Payer Perspective

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Opportunities to Optimize Cancer Policies Panel Discussion

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

Advertisement

Advertisement

Nov

11

Today In Oncology

CTCL Denileukin Diftitox May Improve HRQoL

Researchers Pinpoint Hundreds of Genetic Variants That May Offer New Insights Into Inherited Breast Cancer Risk

Anbenitamab/HB1801 vs THP in HER2-Positive Advanced Breast Cancer

KEYNOTE-867 Immunotherapy Should Not Be Combined With SBRT in Unresected Early-Stage NSCLC

FDA Approves Pimicotinib for Symptomatic TGCT

Advertisement

© 2026 HSP News Service, L.L.C.